Navigation Links
Pharmasset Reports Fiscal First Quarter 2009 Financial Results
Date:2/9/2009

bination of two oral antiviral molecules to treat hepatitis C virus (HCV) in the absence of interferon. The study will investigate the combination of Pharmasset's R7128 with InterMune's R7227, a protease inhibitor;

-- On January 11, 2009, Pharmasset announced that the company and its development partner, Roche, had agreed with the FDA on the design for a phase 2b trial with R7128, a nucleoside inhibitor of HCV, slated to initiate in the first calendar quarter of 2009;

-- On January 30, 2009, Pharmasset filed an IND for PSI-7851, a nucleotide inhibitor of HCV, with the FDA and expects to initiate a Phase 1 clinical trial to study safety and pharmacokinetics in healthy volunteers at the end of the first calendar quarter of 2009;

-- On January 30, 2009, Pharmasset and Bukwang Pharm. Co., Ltd. entered into an amendment of their license agreement covering clevudine. The amendment expands the territories in which Pharmasset has been granted rights to include Australia, Japan, New Zealand and Taiwan;

-- On February 5, 2009, Pharmasset completed a registered direct offering that raised net proceeds of $43.5 million.

"We had a very productive start to 2009, filing an IND for PSI-7851, our second generation nucleotide for HCV and, strengthening our balance sheet by raising $43.5 million in a tough financial market" stated Schaefer Price, President and Chief Executive Officer. "Our goal remains to build a leading franchise of nucleoside inhibitors for hepatitis C and B. Our plan is to provide updates throughout the year on all of our programs, including the first antiviral data on PSI-7851 in the second half of 2009."

Calendar Year 2009 Anticipated Milestones:

-- Roche initiates phase 2b study of R7128 in first quarter of 2009;

-- Complete enrollment of clevudine registration trials at end of first quarter of 2009;

-- Initiate
'/>"/>

SOURCE Pharmasset, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Pharmasset Announces $45.5 Million Registered Direct Offering of Common Stock
2. Pharmasset and Roche Obtain FDA Consent to Start a Phase 2b Study With R7128 in Treatment Naive HCV Patients
3. Pharmasset to Present at Two Upcoming Investor Conferences
4. Pharmasset to Present at the Natixis Bleichroeder Hidden Gems Conference on Monday, October 13th
5. Pharmasset to Present at the JMP Securities Healthcare Focus Conference on Monday, October 6th
6. Pharmasset Reports Preliminary Results of a 4-week Proof-of-Concept Combination Study of R7128 for the Treatment of Chronic Hepatitis C in Genotype 2 or 3 Non-Responders
7. Pharmasset to Present at the Upcoming Citibank and Morgan Stanley Investor Conferences
8. Pharmasset to Present at the Canaccord Adams Global Growth Conference on Tuesday, August 12th
9. Pharmasset Announces $25.9 Million Registered Direct Offering of Common Stock
10. Pharmasset Joins Russell 3000 Index
11. Pharmasset to Present at the Needham & Co. Biotechnology and Medical Technology Conference on Wednesday, June 11th
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... may help in the fight against terrorism with the ... of explosives with the use of light and special ... and Actuators B: Chemical , the researchers describe a ... concentrations as low as 6.3 ppm (parts per million). ... minutes. , "Traditionally explosives detection has involved looking for ...
(Date:7/10/2014)... PNAS (Proceedings of the National Academy of Sciences) ... deprivation have a significant effect on our metabolism. The ... time of day to test for diseases such as ... , Researchers from the University of Surrey and The ... sleep deprivation, body clock disruption and metabolism, and discovered ...
(Date:7/10/2014)... observed the fractional quantum Hall effect in bilayer graphene ... be tuned by an electric field. , The ... confined to thin sheets are exposed to large magnetic ... thousands of individual electrons behave as a single system. ... well established, many details of this collective behavior remain ...
(Date:7/10/2014)... forever. Nanophysics makes sure of that. Mechanics researchers at Linkping ... Physical Review E . Knowledge that can be of ... be able to sit still forever, and walk around upside ... soon be able to buy smart new fasteners that hold ... is, sooner or later the grip is lost, no matter ...
Breaking Biology Technology:Detecting trace amounts of explosives with light 2Time of day crucial to accurately test for diseases, new research finds 2Columbia researchers observe tunable quantum behavior in bilayer graphene 2Columbia researchers observe tunable quantum behavior in bilayer graphene 3Even geckos can lose their grip 2
... -- On March 6, the Air Force Office ... by Dr. Chad Mirkin from Northwestern University. Professor ... who is known for his development of nanoparticle-based biodetection ... Dip-Pen,Nanolithography (DPN), and his contributions to supramolecular chemistry, nanoelectronics, ...
... AlphaVax, Inc. ("AVX") is pleased to report that it has been ... Award as the Best Early-Stage Vaccine Biotech Company. The award will ... in April. AVX is pleased to be both ... of judges as well as being recognized as a leader in ...
... DIEGO, March 20, 2012   CareFusion announced today ... Food and Drug Administration (FDA) for its new electrodiagnostic ... EDX system is a multi-modality device for monitoring and ... system. (Logo: http://photos.prnewswire.com/prnh/20100706/CAREFUSIONLOGO ) ...
Cached Biology Technology:Air Force Office of Scientific Research hosts nanotechnology pioneer 2Air Force Office of Scientific Research hosts nanotechnology pioneer 3Air Force Office of Scientific Research hosts nanotechnology pioneer 4CareFusion Announces 510(k) Clearance and U.S. Launch of New Advanced Electrodiagnostic System 2
(Date:7/11/2014)... July 11, 2014 Research and Markets ... Biometrics Technology Market - Industry Analysis Size Share Growth ... offering. http://photos.prnewswire.com/prnh/20130307/600769 ... has created a need for high level security in ... personnel authentication such as username and passwords, tokens etc. ...
(Date:7/10/2014)... 27, 2014  Pomerantz LLP has filed a ... or the "Company")(NYSE-MKT: PVCT) and certain of its ... District Court, Middle District of Tennessee ... a class consisting of all persons or entities ... December 17, 2013 and May 22, 2014, both ...
(Date:7/10/2014)... SHELTON, Conn. , July 2, 2014 NXT-ID, Inc., ... market, reports that CEO Mr. Gino Pereira was ... radio show in Tampa Florida . Mr. ... radio host Cedric Harris and how the Wocket™ ... secure alternative.  Cedric Harris tells ...
Breaking Biology News(10 mins):International Biometrics Technology Market - Industry Analysis Size Share Growth Trends and Forecast to 2019 2SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action against Provectus Biopharmaceuticals, Inc. and Certain Officers - PVCT 2SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action against Provectus Biopharmaceuticals, Inc. and Certain Officers - PVCT 3Security and Your Money: Tampa Bay Radio Host Cedric Harris Talks to NXT-ID CEO Mr. Gino Pereira about the Wocket Smart Wallet 2Security and Your Money: Tampa Bay Radio Host Cedric Harris Talks to NXT-ID CEO Mr. Gino Pereira about the Wocket Smart Wallet 3Security and Your Money: Tampa Bay Radio Host Cedric Harris Talks to NXT-ID CEO Mr. Gino Pereira about the Wocket Smart Wallet 4
... world-leading provider of scientific, technical and medical information products and ... the European Menopause and Andropause Society (EMAS) in journal ... women with summary recommendations. Vitamin D deficiency is common ... classified as a public health issue as it can contribute ...
... it comes to conserving the world,s orchids, not all forests ... in the journal Molecular Ecology , Smithsonian ecologists revealed ... age and its fungi. Roughly 10 percent of all ... on Earth. But habitat loss has rendered many threatened or ...
... 2010, an entomologist at the University of California, Riverside discovered a ... seen in the United States until then. Nearly exactly a ... that the wasp is well established in the country. Called ... and arrived in North America from Europe. It lays its ...
Cached Biology News:Elsevier's Maturitas publishes position statement on the role of vitamin D in postmenopausal women 2Fungi-filled forests are critical for endangered orchids 2Wasp found in upstate New York shows up in Southern California 2
Mouse monoclonal [PRMT5-21] to PRMT5 ( Abpromise for all tested applications). entrezGeneID: 10419 SwissProtID: O14744...
Mouse TrkC Affinity Purified Polyclonal Ab...
Mouse MMP-24 (MT5-MMP) MAb (Clone 143908)...
TMB Slow Kinetic One Component HRP Microwell Substrate, 1 L...
Biology Products: